Vaxart shares slide after first-quarter earnings miss

seekingalpha2021-05-03

(May 3) Vaxart shares slide over 12% during morning tradingafter the company postedfirst-quarter results that missed Wall Street estimates, owing tohigher research and development costs and a fall in ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

xCass
2021-05-04
xCass
Great!
Soksok
2021-05-04
Soksok
Good
- LCT15:
  rly
sharonyim
2021-05-04
sharonyim
pls like me ?
- LCT15:
  ok
S土豪熊貓G
2021-05-03
S土豪熊貓G
Buy buy buy to leverage. Congress on 4-6May. Don’t regret. Buy and hold
Elgk
2021-05-03
Elgk
Likeyyy
WalkingIn
2021-05-03
WalkingIn
Ok

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1121188867?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2021-05-03 21:51","share_image_url":"https://static.laohu8.com/5a36db9d73b4222bc376d24ccc48c8a4","id":"1121188867","market":"us","top_or_hot":-1,"title":"Vaxart shares slide after first-quarter earnings miss","media":"seekingalpha","content":"<div>\n<p>(May 3) Vaxart shares slide over 12% during morning tradingafter the company postedfirst-quarter results that missed Wall Street estimates, owing tohigher research and development costs and a fall in ...</p>\n\n<a href=\"https://seekingalpha.com/news/3689156-vaxart-shares-slide-after-first-quarter-earnings-miss\">Source Link</a>\n\n</div>\n","source":"seekingalpha","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Vaxart shares slide after first-quarter earnings miss</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nVaxart shares slide after first-quarter earnings miss\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-05-03 21:51 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://seekingalpha.com/news/3689156-vaxart-shares-slide-after-first-quarter-earnings-miss><strong>seekingalpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>(May 3) Vaxart shares slide over 12% during morning tradingafter the company postedfirst-quarter results that missed Wall Street estimates, owing tohigher research and development costs and a fall in ...</p>\n\n<a href=\"https://seekingalpha.com/news/3689156-vaxart-shares-slide-after-first-quarter-earnings-miss\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"VXRT","symbol_name":"Vaxart, Inc","start_time":0,"source_url":"https://seekingalpha.com/news/3689156-vaxart-shares-slide-after-first-quarter-earnings-miss","article_id":"1121188867","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1121188867","pubTimestamp":1620049912,"sourceInfo":{"source_id":"seekingalpha","name":"Seeking Alpha"},"weMediaInfo":null,"summary":"(May 3) Vaxart shares slide over 12% during morning tradingafter the company postedfirst-quarter res","collect":0,"end_time":0,"defaultTopTitle":"seekingalpha.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"VXRT":"Vaxart, Inc"},"translate_title":"Vaxart第一季度业绩不佳后股价下滑","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"VXRT":0.9},"content_text":"(May 3) Vaxart shares slide over 12% during morning tradingafter the company postedfirst-quarter results that missed Wall Street estimates, owing tohigher research and development costs and a fall in Inavir related royalty revenue.\n\nThe company's quarterly revenue plummeted over 80% to $0.51M, mainly due to a reduction in royalty revenue related to Inavir sales in Japan as a result of abnormally low incidences of seasonal influenza. Revenue missed analysts' estimate by $0.11M.\nThe company saw its R&D expenses rise to $10.1M from $1.5M last year, mainly due to manufacturing and clinical trial expenses related to the COVID-19 and norovirus vaccine candidates.\nGeneral and administrative expenses also rose to $5.9M from $2M in the prior-year period.\nVaxart reported a net loss of $16M, or $0.14 per share, compared to a net loss of $1.3M, or $0.02 per share last year.\nThe company ended the quarter with cash, cash equivalents, and available-for-sale debt securities of $177.3M, compared to $126.9M as of December 31, 2020.\nVaxart also highlighted plans to progress its oral norovirus vaccine program with the initiation of four clinical trials in 2021.\nPreviously (May 3):Vaxart EPS misses by $0.04, misses on revenue.","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[{"id":106973037,"gmtCreate":1620086528029,"gmtModify":1704338338307,"author":{"id":"3575793577969306","authorId":"3575793577969306","authorIdStr":"3575793577969306","name":"xCass","avatar":"https://static.tigerbbs.com/4d13a4236fd5fe0391b573daccd86bfc","vip":1,"crmLevel":1,"crmLevelSwitch":0,"idStr":"3575793577969306"},"htmlText":"Great!","listText":"Great!","text":"Great!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/106973037","repostId":1121188867,"repostType":4,"repost":{"id":"1121188867","pubTimestamp":1620049912,"share":"https://ttm.financial/m/news/1121188867?lang=&edition=fundamental","pubTime":"2021-05-03 21:51","market":"us","language":"en","title":"Vaxart shares slide after first-quarter earnings miss","url":"https://stock-news.laohu8.com/highlight/detail?id=1121188867","media":"seekingalpha","summary":"(May 3) Vaxart shares slide over 12% during morning tradingafter the company postedfirst-quarter res","content":"<p>(May&nbsp;3)&nbsp;Vaxart&nbsp;shares slide over&nbsp;12%&nbsp;during morning tradingafter the company postedfirst-quarter results that missed Wall Street estimates, owing tohigher research and development costs and a fall in Inavir related royalty revenue.</p>\n<p><img src=\"https://static.tigerbbs.com/f9684b3617216942a2aa8adfd5d1954d\" tg-width=\"633\" tg-height=\"479\"></p>\n<p>The company's quarterly revenue plummeted over 80% to $0.51M, mainly due to a reduction in royalty revenue related to Inavir sales in&nbsp;Japan&nbsp;as a result of abnormally low incidences of seasonal influenza. Revenue missed analysts' estimate by $0.11M.</p>\n<p>The company saw its R&amp;D expenses rise to $10.1M from $1.5M last year, mainly due to manufacturing and clinical trial expenses related to the COVID-19 and norovirus vaccine candidates.</p>\n<p>General and administrative expenses also rose to $5.9M from $2M in the prior-year period.</p>\n<p>Vaxart reported a net loss of $16M, or $0.14 per share, compared to a net loss of $1.3M, or $0.02 per share last year.</p>\n<p>The company ended the quarter with cash, cash equivalents, and available-for-sale debt securities of $177.3M, compared to $126.9M as of December 31, 2020.</p>\n<p>Vaxart also highlighted plans to progress its oral norovirus vaccine program with the initiation of four clinical trials in 2021.</p>\n<p>Previously (May 3):Vaxart EPS misses by $0.04, misses on revenue.</p>","source":"seekingalpha","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Vaxart shares slide after first-quarter earnings miss</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nVaxart shares slide after first-quarter earnings miss\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-05-03 21:51 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://seekingalpha.com/news/3689156-vaxart-shares-slide-after-first-quarter-earnings-miss><strong>seekingalpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>(May 3) Vaxart shares slide over 12% during morning tradingafter the company postedfirst-quarter results that missed Wall Street estimates, owing tohigher research and development costs and a fall in ...</p>\n\n<a href=\"https://seekingalpha.com/news/3689156-vaxart-shares-slide-after-first-quarter-earnings-miss\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"VXRT":"Vaxart, Inc"},"source_url":"https://seekingalpha.com/news/3689156-vaxart-shares-slide-after-first-quarter-earnings-miss","is_english":true,"share_image_url":"https://static.laohu8.com/5a36db9d73b4222bc376d24ccc48c8a4","article_id":"1121188867","content_text":"(May 3) Vaxart shares slide over 12% during morning tradingafter the company postedfirst-quarter results that missed Wall Street estimates, owing tohigher research and development costs and a fall in Inavir related royalty revenue.\n\nThe company's quarterly revenue plummeted over 80% to $0.51M, mainly due to a reduction in royalty revenue related to Inavir sales in Japan as a result of abnormally low incidences of seasonal influenza. Revenue missed analysts' estimate by $0.11M.\nThe company saw its R&D expenses rise to $10.1M from $1.5M last year, mainly due to manufacturing and clinical trial expenses related to the COVID-19 and norovirus vaccine candidates.\nGeneral and administrative expenses also rose to $5.9M from $2M in the prior-year period.\nVaxart reported a net loss of $16M, or $0.14 per share, compared to a net loss of $1.3M, or $0.02 per share last year.\nThe company ended the quarter with cash, cash equivalents, and available-for-sale debt securities of $177.3M, compared to $126.9M as of December 31, 2020.\nVaxart also highlighted plans to progress its oral norovirus vaccine program with the initiation of four clinical trials in 2021.\nPreviously (May 3):Vaxart EPS misses by $0.04, misses on revenue.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":106986561,"gmtCreate":1620084375953,"gmtModify":1704338279766,"author":{"id":"3579684763801587","authorId":"3579684763801587","authorIdStr":"3579684763801587","name":"Soksok","avatar":"https://static.tigerbbs.com/03c4a8d2787d3c5042bccff3b0bb60f1","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"3579684763801587"},"htmlText":"Good&nbsp;","listText":"Good&nbsp;","text":"Good","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/106986561","repostId":1121188867,"repostType":4,"repost":{"id":"1121188867","pubTimestamp":1620049912,"share":"https://ttm.financial/m/news/1121188867?lang=&edition=fundamental","pubTime":"2021-05-03 21:51","market":"us","language":"en","title":"Vaxart shares slide after first-quarter earnings miss","url":"https://stock-news.laohu8.com/highlight/detail?id=1121188867","media":"seekingalpha","summary":"(May 3) Vaxart shares slide over 12% during morning tradingafter the company postedfirst-quarter res","content":"<p>(May&nbsp;3)&nbsp;Vaxart&nbsp;shares slide over&nbsp;12%&nbsp;during morning tradingafter the company postedfirst-quarter results that missed Wall Street estimates, owing tohigher research and development costs and a fall in Inavir related royalty revenue.</p>\n<p><img src=\"https://static.tigerbbs.com/f9684b3617216942a2aa8adfd5d1954d\" tg-width=\"633\" tg-height=\"479\"></p>\n<p>The company's quarterly revenue plummeted over 80% to $0.51M, mainly due to a reduction in royalty revenue related to Inavir sales in&nbsp;Japan&nbsp;as a result of abnormally low incidences of seasonal influenza. Revenue missed analysts' estimate by $0.11M.</p>\n<p>The company saw its R&amp;D expenses rise to $10.1M from $1.5M last year, mainly due to manufacturing and clinical trial expenses related to the COVID-19 and norovirus vaccine candidates.</p>\n<p>General and administrative expenses also rose to $5.9M from $2M in the prior-year period.</p>\n<p>Vaxart reported a net loss of $16M, or $0.14 per share, compared to a net loss of $1.3M, or $0.02 per share last year.</p>\n<p>The company ended the quarter with cash, cash equivalents, and available-for-sale debt securities of $177.3M, compared to $126.9M as of December 31, 2020.</p>\n<p>Vaxart also highlighted plans to progress its oral norovirus vaccine program with the initiation of four clinical trials in 2021.</p>\n<p>Previously (May 3):Vaxart EPS misses by $0.04, misses on revenue.</p>","source":"seekingalpha","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Vaxart shares slide after first-quarter earnings miss</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nVaxart shares slide after first-quarter earnings miss\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-05-03 21:51 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://seekingalpha.com/news/3689156-vaxart-shares-slide-after-first-quarter-earnings-miss><strong>seekingalpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>(May 3) Vaxart shares slide over 12% during morning tradingafter the company postedfirst-quarter results that missed Wall Street estimates, owing tohigher research and development costs and a fall in ...</p>\n\n<a href=\"https://seekingalpha.com/news/3689156-vaxart-shares-slide-after-first-quarter-earnings-miss\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"VXRT":"Vaxart, Inc"},"source_url":"https://seekingalpha.com/news/3689156-vaxart-shares-slide-after-first-quarter-earnings-miss","is_english":true,"share_image_url":"https://static.laohu8.com/5a36db9d73b4222bc376d24ccc48c8a4","article_id":"1121188867","content_text":"(May 3) Vaxart shares slide over 12% during morning tradingafter the company postedfirst-quarter results that missed Wall Street estimates, owing tohigher research and development costs and a fall in Inavir related royalty revenue.\n\nThe company's quarterly revenue plummeted over 80% to $0.51M, mainly due to a reduction in royalty revenue related to Inavir sales in Japan as a result of abnormally low incidences of seasonal influenza. Revenue missed analysts' estimate by $0.11M.\nThe company saw its R&D expenses rise to $10.1M from $1.5M last year, mainly due to manufacturing and clinical trial expenses related to the COVID-19 and norovirus vaccine candidates.\nGeneral and administrative expenses also rose to $5.9M from $2M in the prior-year period.\nVaxart reported a net loss of $16M, or $0.14 per share, compared to a net loss of $1.3M, or $0.02 per share last year.\nThe company ended the quarter with cash, cash equivalents, and available-for-sale debt securities of $177.3M, compared to $126.9M as of December 31, 2020.\nVaxart also highlighted plans to progress its oral norovirus vaccine program with the initiation of four clinical trials in 2021.\nPreviously (May 3):Vaxart EPS misses by $0.04, misses on revenue.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":4213855,"gmtCreate":1620086296112,"gmtModify":1680786849877,"authorId":3581496418554017,"author":{"id":3581496418554017,"authorId":3581496418554017,"name":"LCT15","avatar":"https://static.tigerbbs.com/c80d0fa5d2104afed54088e78f8c338b","vip":1,"crmLevel":1,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":106986561,"type":1,"supId":0,"prevId":0,"content":"<u>rly</u>","text":"<u>rly</u>","html":"<u>rly</u>"}],"langContent":"EN"},{"id":106079316,"gmtCreate":1620081337035,"gmtModify":1704338205444,"author":{"id":"3581852273201777","authorId":"3581852273201777","authorIdStr":"3581852273201777","name":"sharonyim","avatar":"https://static.tigerbbs.com/00f79e45ab6c11af64432ccbb28a68c5","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"3581852273201777"},"htmlText":"pls like me ?","listText":"pls like me ?","text":"pls like me ?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/106079316","repostId":1121188867,"repostType":4,"repost":{"id":"1121188867","pubTimestamp":1620049912,"share":"https://ttm.financial/m/news/1121188867?lang=&edition=fundamental","pubTime":"2021-05-03 21:51","market":"us","language":"en","title":"Vaxart shares slide after first-quarter earnings miss","url":"https://stock-news.laohu8.com/highlight/detail?id=1121188867","media":"seekingalpha","summary":"(May 3) Vaxart shares slide over 12% during morning tradingafter the company postedfirst-quarter res","content":"<p>(May&nbsp;3)&nbsp;Vaxart&nbsp;shares slide over&nbsp;12%&nbsp;during morning tradingafter the company postedfirst-quarter results that missed Wall Street estimates, owing tohigher research and development costs and a fall in Inavir related royalty revenue.</p>\n<p><img src=\"https://static.tigerbbs.com/f9684b3617216942a2aa8adfd5d1954d\" tg-width=\"633\" tg-height=\"479\"></p>\n<p>The company's quarterly revenue plummeted over 80% to $0.51M, mainly due to a reduction in royalty revenue related to Inavir sales in&nbsp;Japan&nbsp;as a result of abnormally low incidences of seasonal influenza. Revenue missed analysts' estimate by $0.11M.</p>\n<p>The company saw its R&amp;D expenses rise to $10.1M from $1.5M last year, mainly due to manufacturing and clinical trial expenses related to the COVID-19 and norovirus vaccine candidates.</p>\n<p>General and administrative expenses also rose to $5.9M from $2M in the prior-year period.</p>\n<p>Vaxart reported a net loss of $16M, or $0.14 per share, compared to a net loss of $1.3M, or $0.02 per share last year.</p>\n<p>The company ended the quarter with cash, cash equivalents, and available-for-sale debt securities of $177.3M, compared to $126.9M as of December 31, 2020.</p>\n<p>Vaxart also highlighted plans to progress its oral norovirus vaccine program with the initiation of four clinical trials in 2021.</p>\n<p>Previously (May 3):Vaxart EPS misses by $0.04, misses on revenue.</p>","source":"seekingalpha","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Vaxart shares slide after first-quarter earnings miss</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nVaxart shares slide after first-quarter earnings miss\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-05-03 21:51 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://seekingalpha.com/news/3689156-vaxart-shares-slide-after-first-quarter-earnings-miss><strong>seekingalpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>(May 3) Vaxart shares slide over 12% during morning tradingafter the company postedfirst-quarter results that missed Wall Street estimates, owing tohigher research and development costs and a fall in ...</p>\n\n<a href=\"https://seekingalpha.com/news/3689156-vaxart-shares-slide-after-first-quarter-earnings-miss\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"VXRT":"Vaxart, Inc"},"source_url":"https://seekingalpha.com/news/3689156-vaxart-shares-slide-after-first-quarter-earnings-miss","is_english":true,"share_image_url":"https://static.laohu8.com/5a36db9d73b4222bc376d24ccc48c8a4","article_id":"1121188867","content_text":"(May 3) Vaxart shares slide over 12% during morning tradingafter the company postedfirst-quarter results that missed Wall Street estimates, owing tohigher research and development costs and a fall in Inavir related royalty revenue.\n\nThe company's quarterly revenue plummeted over 80% to $0.51M, mainly due to a reduction in royalty revenue related to Inavir sales in Japan as a result of abnormally low incidences of seasonal influenza. Revenue missed analysts' estimate by $0.11M.\nThe company saw its R&D expenses rise to $10.1M from $1.5M last year, mainly due to manufacturing and clinical trial expenses related to the COVID-19 and norovirus vaccine candidates.\nGeneral and administrative expenses also rose to $5.9M from $2M in the prior-year period.\nVaxart reported a net loss of $16M, or $0.14 per share, compared to a net loss of $1.3M, or $0.02 per share last year.\nThe company ended the quarter with cash, cash equivalents, and available-for-sale debt securities of $177.3M, compared to $126.9M as of December 31, 2020.\nVaxart also highlighted plans to progress its oral norovirus vaccine program with the initiation of four clinical trials in 2021.\nPreviously (May 3):Vaxart EPS misses by $0.04, misses on revenue.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":4213858,"gmtCreate":1620086319824,"gmtModify":1663226235669,"authorId":3581496418554017,"author":{"id":3581496418554017,"authorId":3581496418554017,"name":"LCT15","avatar":"https://static.tigerbbs.com/c80d0fa5d2104afed54088e78f8c338b","vip":1,"crmLevel":1,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":106079316,"type":1,"supId":0,"prevId":0,"content":"<u>ok</u>","text":"<u>ok</u>","html":"<u>ok</u>"}],"langContent":"EN"},{"id":108735126,"gmtCreate":1620053544065,"gmtModify":1704337990097,"author":{"id":"3578811676095048","authorId":"3578811676095048","authorIdStr":"3578811676095048","name":"S土豪熊貓G","avatar":"https://static.tigerbbs.com/2bf36dcb8e5b590c1e5f4df466413275","vip":1,"crmLevel":7,"crmLevelSwitch":0,"idStr":"3578811676095048"},"htmlText":"Buy buy buy to leverage. Congress on 4-6May.&nbsp;Don’t regret. Buy and hold","listText":"Buy buy buy to leverage. Congress on 4-6May.&nbsp;Don’t regret. Buy and hold","text":"Buy buy buy to leverage. Congress on 4-6May. Don’t regret. Buy and hold","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/108735126","repostId":1121188867,"repostType":2,"repost":{"id":"1121188867","pubTimestamp":1620049912,"share":"https://ttm.financial/m/news/1121188867?lang=&edition=fundamental","pubTime":"2021-05-03 21:51","market":"us","language":"en","title":"Vaxart shares slide after first-quarter earnings miss","url":"https://stock-news.laohu8.com/highlight/detail?id=1121188867","media":"seekingalpha","summary":"(May 3) Vaxart shares slide over 12% during morning tradingafter the company postedfirst-quarter res","content":"<p>(May&nbsp;3)&nbsp;Vaxart&nbsp;shares slide over&nbsp;12%&nbsp;during morning tradingafter the company postedfirst-quarter results that missed Wall Street estimates, owing tohigher research and development costs and a fall in Inavir related royalty revenue.</p>\n<p><img src=\"https://static.tigerbbs.com/f9684b3617216942a2aa8adfd5d1954d\" tg-width=\"633\" tg-height=\"479\"></p>\n<p>The company's quarterly revenue plummeted over 80% to $0.51M, mainly due to a reduction in royalty revenue related to Inavir sales in&nbsp;Japan&nbsp;as a result of abnormally low incidences of seasonal influenza. Revenue missed analysts' estimate by $0.11M.</p>\n<p>The company saw its R&amp;D expenses rise to $10.1M from $1.5M last year, mainly due to manufacturing and clinical trial expenses related to the COVID-19 and norovirus vaccine candidates.</p>\n<p>General and administrative expenses also rose to $5.9M from $2M in the prior-year period.</p>\n<p>Vaxart reported a net loss of $16M, or $0.14 per share, compared to a net loss of $1.3M, or $0.02 per share last year.</p>\n<p>The company ended the quarter with cash, cash equivalents, and available-for-sale debt securities of $177.3M, compared to $126.9M as of December 31, 2020.</p>\n<p>Vaxart also highlighted plans to progress its oral norovirus vaccine program with the initiation of four clinical trials in 2021.</p>\n<p>Previously (May 3):Vaxart EPS misses by $0.04, misses on revenue.</p>","source":"seekingalpha","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Vaxart shares slide after first-quarter earnings miss</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nVaxart shares slide after first-quarter earnings miss\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-05-03 21:51 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://seekingalpha.com/news/3689156-vaxart-shares-slide-after-first-quarter-earnings-miss><strong>seekingalpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>(May 3) Vaxart shares slide over 12% during morning tradingafter the company postedfirst-quarter results that missed Wall Street estimates, owing tohigher research and development costs and a fall in ...</p>\n\n<a href=\"https://seekingalpha.com/news/3689156-vaxart-shares-slide-after-first-quarter-earnings-miss\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"VXRT":"Vaxart, Inc"},"source_url":"https://seekingalpha.com/news/3689156-vaxart-shares-slide-after-first-quarter-earnings-miss","is_english":true,"share_image_url":"https://static.laohu8.com/5a36db9d73b4222bc376d24ccc48c8a4","article_id":"1121188867","content_text":"(May 3) Vaxart shares slide over 12% during morning tradingafter the company postedfirst-quarter results that missed Wall Street estimates, owing tohigher research and development costs and a fall in Inavir related royalty revenue.\n\nThe company's quarterly revenue plummeted over 80% to $0.51M, mainly due to a reduction in royalty revenue related to Inavir sales in Japan as a result of abnormally low incidences of seasonal influenza. Revenue missed analysts' estimate by $0.11M.\nThe company saw its R&D expenses rise to $10.1M from $1.5M last year, mainly due to manufacturing and clinical trial expenses related to the COVID-19 and norovirus vaccine candidates.\nGeneral and administrative expenses also rose to $5.9M from $2M in the prior-year period.\nVaxart reported a net loss of $16M, or $0.14 per share, compared to a net loss of $1.3M, or $0.02 per share last year.\nThe company ended the quarter with cash, cash equivalents, and available-for-sale debt securities of $177.3M, compared to $126.9M as of December 31, 2020.\nVaxart also highlighted plans to progress its oral norovirus vaccine program with the initiation of four clinical trials in 2021.\nPreviously (May 3):Vaxart EPS misses by $0.04, misses on revenue.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":108701656,"gmtCreate":1620052095675,"gmtModify":1704337956704,"author":{"id":"3582942802538500","authorId":"3582942802538500","authorIdStr":"3582942802538500","name":"Elgk","avatar":"https://static.tigerbbs.com/f4e8020d7d7938b137783287f1ce6264","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"3582942802538500"},"htmlText":"Likeyyy","listText":"Likeyyy","text":"Likeyyy","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/108701656","repostId":1121188867,"repostType":4,"repost":{"id":"1121188867","pubTimestamp":1620049912,"share":"https://ttm.financial/m/news/1121188867?lang=&edition=fundamental","pubTime":"2021-05-03 21:51","market":"us","language":"en","title":"Vaxart shares slide after first-quarter earnings miss","url":"https://stock-news.laohu8.com/highlight/detail?id=1121188867","media":"seekingalpha","summary":"(May 3) Vaxart shares slide over 12% during morning tradingafter the company postedfirst-quarter res","content":"<p>(May&nbsp;3)&nbsp;Vaxart&nbsp;shares slide over&nbsp;12%&nbsp;during morning tradingafter the company postedfirst-quarter results that missed Wall Street estimates, owing tohigher research and development costs and a fall in Inavir related royalty revenue.</p>\n<p><img src=\"https://static.tigerbbs.com/f9684b3617216942a2aa8adfd5d1954d\" tg-width=\"633\" tg-height=\"479\"></p>\n<p>The company's quarterly revenue plummeted over 80% to $0.51M, mainly due to a reduction in royalty revenue related to Inavir sales in&nbsp;Japan&nbsp;as a result of abnormally low incidences of seasonal influenza. Revenue missed analysts' estimate by $0.11M.</p>\n<p>The company saw its R&amp;D expenses rise to $10.1M from $1.5M last year, mainly due to manufacturing and clinical trial expenses related to the COVID-19 and norovirus vaccine candidates.</p>\n<p>General and administrative expenses also rose to $5.9M from $2M in the prior-year period.</p>\n<p>Vaxart reported a net loss of $16M, or $0.14 per share, compared to a net loss of $1.3M, or $0.02 per share last year.</p>\n<p>The company ended the quarter with cash, cash equivalents, and available-for-sale debt securities of $177.3M, compared to $126.9M as of December 31, 2020.</p>\n<p>Vaxart also highlighted plans to progress its oral norovirus vaccine program with the initiation of four clinical trials in 2021.</p>\n<p>Previously (May 3):Vaxart EPS misses by $0.04, misses on revenue.</p>","source":"seekingalpha","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Vaxart shares slide after first-quarter earnings miss</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nVaxart shares slide after first-quarter earnings miss\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-05-03 21:51 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://seekingalpha.com/news/3689156-vaxart-shares-slide-after-first-quarter-earnings-miss><strong>seekingalpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>(May 3) Vaxart shares slide over 12% during morning tradingafter the company postedfirst-quarter results that missed Wall Street estimates, owing tohigher research and development costs and a fall in ...</p>\n\n<a href=\"https://seekingalpha.com/news/3689156-vaxart-shares-slide-after-first-quarter-earnings-miss\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"VXRT":"Vaxart, Inc"},"source_url":"https://seekingalpha.com/news/3689156-vaxart-shares-slide-after-first-quarter-earnings-miss","is_english":true,"share_image_url":"https://static.laohu8.com/5a36db9d73b4222bc376d24ccc48c8a4","article_id":"1121188867","content_text":"(May 3) Vaxart shares slide over 12% during morning tradingafter the company postedfirst-quarter results that missed Wall Street estimates, owing tohigher research and development costs and a fall in Inavir related royalty revenue.\n\nThe company's quarterly revenue plummeted over 80% to $0.51M, mainly due to a reduction in royalty revenue related to Inavir sales in Japan as a result of abnormally low incidences of seasonal influenza. Revenue missed analysts' estimate by $0.11M.\nThe company saw its R&D expenses rise to $10.1M from $1.5M last year, mainly due to manufacturing and clinical trial expenses related to the COVID-19 and norovirus vaccine candidates.\nGeneral and administrative expenses also rose to $5.9M from $2M in the prior-year period.\nVaxart reported a net loss of $16M, or $0.14 per share, compared to a net loss of $1.3M, or $0.02 per share last year.\nThe company ended the quarter with cash, cash equivalents, and available-for-sale debt securities of $177.3M, compared to $126.9M as of December 31, 2020.\nVaxart also highlighted plans to progress its oral norovirus vaccine program with the initiation of four clinical trials in 2021.\nPreviously (May 3):Vaxart EPS misses by $0.04, misses on revenue.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":108479315,"gmtCreate":1620051453637,"gmtModify":1704337939022,"author":{"id":"3581413944630908","authorId":"3581413944630908","authorIdStr":"3581413944630908","name":"WalkingIn","avatar":"https://static.tigerbbs.com/74ca2c98f1ef1d4b5f17b3666953d588","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"3581413944630908"},"htmlText":"Ok","listText":"Ok","text":"Ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/108479315","repostId":1121188867,"repostType":4,"repost":{"id":"1121188867","pubTimestamp":1620049912,"share":"https://ttm.financial/m/news/1121188867?lang=&edition=fundamental","pubTime":"2021-05-03 21:51","market":"us","language":"en","title":"Vaxart shares slide after first-quarter earnings miss","url":"https://stock-news.laohu8.com/highlight/detail?id=1121188867","media":"seekingalpha","summary":"(May 3) Vaxart shares slide over 12% during morning tradingafter the company postedfirst-quarter res","content":"<p>(May&nbsp;3)&nbsp;Vaxart&nbsp;shares slide over&nbsp;12%&nbsp;during morning tradingafter the company postedfirst-quarter results that missed Wall Street estimates, owing tohigher research and development costs and a fall in Inavir related royalty revenue.</p>\n<p><img src=\"https://static.tigerbbs.com/f9684b3617216942a2aa8adfd5d1954d\" tg-width=\"633\" tg-height=\"479\"></p>\n<p>The company's quarterly revenue plummeted over 80% to $0.51M, mainly due to a reduction in royalty revenue related to Inavir sales in&nbsp;Japan&nbsp;as a result of abnormally low incidences of seasonal influenza. Revenue missed analysts' estimate by $0.11M.</p>\n<p>The company saw its R&amp;D expenses rise to $10.1M from $1.5M last year, mainly due to manufacturing and clinical trial expenses related to the COVID-19 and norovirus vaccine candidates.</p>\n<p>General and administrative expenses also rose to $5.9M from $2M in the prior-year period.</p>\n<p>Vaxart reported a net loss of $16M, or $0.14 per share, compared to a net loss of $1.3M, or $0.02 per share last year.</p>\n<p>The company ended the quarter with cash, cash equivalents, and available-for-sale debt securities of $177.3M, compared to $126.9M as of December 31, 2020.</p>\n<p>Vaxart also highlighted plans to progress its oral norovirus vaccine program with the initiation of four clinical trials in 2021.</p>\n<p>Previously (May 3):Vaxart EPS misses by $0.04, misses on revenue.</p>","source":"seekingalpha","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Vaxart shares slide after first-quarter earnings miss</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nVaxart shares slide after first-quarter earnings miss\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-05-03 21:51 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://seekingalpha.com/news/3689156-vaxart-shares-slide-after-first-quarter-earnings-miss><strong>seekingalpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>(May 3) Vaxart shares slide over 12% during morning tradingafter the company postedfirst-quarter results that missed Wall Street estimates, owing tohigher research and development costs and a fall in ...</p>\n\n<a href=\"https://seekingalpha.com/news/3689156-vaxart-shares-slide-after-first-quarter-earnings-miss\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"VXRT":"Vaxart, Inc"},"source_url":"https://seekingalpha.com/news/3689156-vaxart-shares-slide-after-first-quarter-earnings-miss","is_english":true,"share_image_url":"https://static.laohu8.com/5a36db9d73b4222bc376d24ccc48c8a4","article_id":"1121188867","content_text":"(May 3) Vaxart shares slide over 12% during morning tradingafter the company postedfirst-quarter results that missed Wall Street estimates, owing tohigher research and development costs and a fall in Inavir related royalty revenue.\n\nThe company's quarterly revenue plummeted over 80% to $0.51M, mainly due to a reduction in royalty revenue related to Inavir sales in Japan as a result of abnormally low incidences of seasonal influenza. Revenue missed analysts' estimate by $0.11M.\nThe company saw its R&D expenses rise to $10.1M from $1.5M last year, mainly due to manufacturing and clinical trial expenses related to the COVID-19 and norovirus vaccine candidates.\nGeneral and administrative expenses also rose to $5.9M from $2M in the prior-year period.\nVaxart reported a net loss of $16M, or $0.14 per share, compared to a net loss of $1.3M, or $0.02 per share last year.\nThe company ended the quarter with cash, cash equivalents, and available-for-sale debt securities of $177.3M, compared to $126.9M as of December 31, 2020.\nVaxart also highlighted plans to progress its oral norovirus vaccine program with the initiation of four clinical trials in 2021.\nPreviously (May 3):Vaxart EPS misses by $0.04, misses on revenue.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"}],"isCommentEnd":false,"newsSizeData":{"likeSize":38,"commentSize":9,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.28.1","shortVersion":"4.28.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1121188867"}